With the introduction of the anti-CD20 monoclonal antibody rituximab, B-cell non-Hodgkin lymphoma was the first malignancy successfully treated with an immunotherapeutic agent. Since then, numerous advances have expanded the repertoire of immunotherapeutic agents available for the treatment of a variety of malignancies, including many lymphoma subtypes.

Authors:

  • Matthew J. Barth

    Corresponding author
    1. Department of Pediatrics, Roswell Park Cancer Institute, Buffalo, NY, USA
    2. Division of Pediatric Hematology/Oncology, University at Buffalo, Buffalo, NY, USA
    • Correspondence: Matthew J. Barth, MD, Assistant Professor of Pediatrics, University at Buffalo, Roswell Park Cancer Institute/Women and Children's Hospital of Buffalo, Buffalo NY, USA.

  • Yaya Chu

    1. Department of Pediatrics, New York Medical College, Valhalla, NY, USA
  • Patrick J. Hanley

    1. Program for Cell Enhancement and Technologies for Immunotherapy, Division of Blood and Marrow Transplantation, Sheikhz Zayed Institute for Pediatric Surgical Innovation, Washington, D.C., USA
    2. Center for Cancer and Immunology Research, Children's National Health System, The George Washington University, Washington, D.C., USA
  • Mitchell S. Cairo

    1. Department of Pediatrics, New York Medical College, Valhalla, NY, USA
    2. Department of Medicine, New York Medical College, Valhalla, NY, USA
    3. Department of Pathology, New York Medical College, Valhalla, NY, USA
    4. Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA
    5. Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA
    Read full article